Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Insights and Forecast to 2031

Report ID: 1240965 | Published Date: Jan 2025 | No. of Page: 89 | Base Year: 2024 | Rating: 3.7 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Study Coverage
    1.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Introduction
    1.2 Market by Type
        1.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 XIFAXAN
        1.2.3 Viberzi
        1.2.4 Lotronex
        1.2.5 Other
    1.3 Market by Sales Channel
        1.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Growth Rate by Sales Channel, 2017 VS 2021 VS 2028
        1.3.2 Hospitals Pharmacy
        1.3.3 Retail Pharmacy
        1.3.4 Other
    1.4 Study Objectives
    1.5 Years Considered
2 Executive Summary
    2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Estimates and Forecasts 2017-2028
    2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Estimates and Forecasts 2017-2028
    2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region: 2017 VS 2021 VS 2028
    2.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region
        2.4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2017-2022)
        2.4.2 Global Sales Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Region (2023-2028)
    2.5 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region
        2.5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2017-2022)
        2.5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2023-2028)
    2.6 North America
    2.7 Europe
    2.8 Asia-Pacific
    2.9 Latin America
    2.10 Middle East & Africa
3 Competition by Manufacturers
    3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Manufacturers
        3.1.1 Global Top Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers by Sales (2017-2022)
        3.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Manufacturers (2017-2022)
        3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in 2021
    3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Manufacturers
        3.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Manufacturers (2017-2022)
        3.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Manufacturers (2017-2022)
        3.2.3 Global Top 10 and Top 5 Companies by Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue in 2021
    3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price by Manufacturers (2017-2022)
    3.4 Analysis of Competitive Landscape
        3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
        3.4.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers Geographical Distribution
    3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
    4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type
        4.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historical Sales by Type (2017-2022)
        4.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Forecasted Sales by Type (2023-2028)
        4.1.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2017-2028)
    4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type
        4.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historical Revenue by Type (2017-2022)
        4.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Forecasted Revenue by Type (2023-2028)
        4.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2017-2028)
    4.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type
        4.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2017-2022)
        4.3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price Forecast by Type (2023-2028)
5 Market Size by Sales Channel
    5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel
        5.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historical Sales by Sales Channel (2017-2022)
        5.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Forecasted Sales by Sales Channel (2023-2028)
        5.1.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2017-2028)
    5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel
        5.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historical Revenue by Sales Channel (2017-2022)
        5.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Forecasted Revenue by Sales Channel (2023-2028)
        5.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Sales Channel (2017-2028)
    5.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Sales Channel
        5.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Sales Channel (2017-2022)
        5.3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price Forecast by Sales Channel (2023-2028)
6 North America
    6.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Type
        6.1.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2017-2028)
        6.1.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2017-2028)
    6.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Sales Channel
        6.2.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2017-2028)
        6.2.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2017-2028)
    6.3 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country
        6.3.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2017-2028)
        6.3.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2017-2028)
        6.3.3 U.S.
        6.3.4 Canada
7 Europe
    7.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Type
        7.1.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2017-2028)
        7.1.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2017-2028)
    7.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Sales Channel
        7.2.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2017-2028)
        7.2.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2017-2028)
    7.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country
        7.3.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2017-2028)
        7.3.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2017-2028)
        7.3.3 Germany
        7.3.4 France
        7.3.5 U.K.
        7.3.6 Italy
        7.3.7 Russia
8 Asia Pacific
    8.1 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Type
        8.1.1 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2017-2028)
        8.1.2 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2017-2028)
    8.2 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Sales Channel
        8.2.1 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2017-2028)
        8.2.2 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2017-2028)
    8.3 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Region
        8.3.1 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2017-2028)
        8.3.2 Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2017-2028)
        8.3.3 China
        8.3.4 Japan
        8.3.5 South Korea
        8.3.6 India
        8.3.7 Australia
        8.3.8 Taiwan
        8.3.9 Indonesia
        8.3.10 Thailand
        8.3.11 Malaysia
9 Latin America
    9.1 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Type
        9.1.1 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2017-2028)
        9.1.2 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2017-2028)
    9.2 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Sales Channel
        9.2.1 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2017-2028)
        9.2.2 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2017-2028)
    9.3 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country
        9.3.1 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2017-2028)
        9.3.2 Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2017-2028)
        9.3.3 Mexico
        9.3.4 Brazil
        9.3.5 Argentina
10 Middle East and Africa
    10.1 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Type
        10.1.1 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2017-2028)
        10.1.2 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2017-2028)
    10.2 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Sales Channel
        10.2.1 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2017-2028)
        10.2.2 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2017-2028)
    10.3 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country
        10.3.1 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2017-2028)
        10.3.2 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2017-2028)
        10.3.3 Turkey
        10.3.4 Saudi Arabia
11 Company Profiles
    11.1 Bausch Health
        11.1.1 Bausch Health Corporation Information
        11.1.2 Bausch Health Overview
        11.1.3 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
        11.1.4 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
        11.1.5 Bausch Health Recent Developments
    11.2 Allergan
        11.2.1 Allergan Corporation Information
        11.2.2 Allergan Overview
        11.2.3 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
        11.2.4 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
        11.2.5 Allergan Recent Developments
    11.3 Sebela Pharmaceuticals
        11.3.1 Sebela Pharmaceuticals Corporation Information
        11.3.2 Sebela Pharmaceuticals Overview
        11.3.3 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
        11.3.4 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
        11.3.5 Sebela Pharmaceuticals Recent Developments
    11.4 Astellas Pharmaceuticals
        11.4.1 Astellas Pharmaceuticals Corporation Information
        11.4.2 Astellas Pharmaceuticals Overview
        11.4.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
        11.4.4 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
        11.4.5 Astellas Pharmaceuticals Recent Developments
    11.5 Amneal Pharms
        11.5.1 Amneal Pharms Corporation Information
        11.5.2 Amneal Pharms Overview
        11.5.3 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
        11.5.4 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
        11.5.5 Amneal Pharms Recent Developments
    11.6 Pharscin Pharma
        11.6.1 Pharscin Pharma Corporation Information
        11.6.2 Pharscin Pharma Overview
        11.6.3 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
        11.6.4 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
        11.6.5 Pharscin Pharma Recent Developments
12 Industry Chain and Sales Channels Analysis
    12.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Chain Analysis
    12.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Key Raw Materials
        12.2.1 Key Raw Materials
        12.2.2 Raw Materials Key Suppliers
    12.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Mode & Process
    12.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Marketing
        12.4.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Channels
        12.4.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors
    12.5 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
    13.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Trends
    13.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Drivers
    13.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Challenges
    13.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Restraints
14 Key Findings in The Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Study
15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
        15.1.2 Data Source
    15.2 Author Details
    15.3 Disclaimer

List of Tables
    Table 1. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
    Table 2. Major Manufacturers of XIFAXAN
    Table 3. Major Manufacturers of Viberzi
    Table 4. Major Manufacturers of Lotronex
    Table 5. Major Manufacturers of Other
    Table 6. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Growth Rate by Sales Channel, 2017 VS 2021 VS 2028 (US$ Million)
    Table 7. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
    Table 8. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2017-2022) & (K Units)
    Table 9. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2017-2022)
    Table 10. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2023-2028) & (K Units)
    Table 11. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2023-2028)
    Table 12. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2017-2022) & (US$ Million)
    Table 13. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2017-2022)
    Table 14. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2023-2028) & (US$ Million)
    Table 15. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2023-2028)
    Table 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Manufacturers (2017-2022) & (K Units)
    Table 17. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Manufacturers (2017-2022)
    Table 18. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Manufacturers (2017-2022) & (US$ Million)
    Table 19. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Manufacturers (2017-2022)
    Table 20. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Manufacturers (2017-2022) &(USD/Unit)
    Table 21. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 22. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs as of 2021)
    Table 23. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base Distribution and Headquarters
    Table 24. Manufacturers Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Offered
    Table 25. Date of Manufacturers Enter into Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market
    Table 26. Mergers & Acquisitions, Expansion Plans
    Table 27. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2017-2022) & (K Units)
    Table 28. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2023-2028) & (K Units)
    Table 29. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Type (2017-2022)
    Table 30. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Type (2023-2028)
    Table 31. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2017-2022) & (US$ Million)
    Table 32. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2023-2028) & (US$ Million)
    Table 33. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Type (2017-2022)
    Table 34. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Type (2023-2028)
    Table 35. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2017-2022) & (USD/Unit)
    Table 36. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price Forecast by Type (2023-2028) & (USD/Unit)
    Table 37. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2017-2022) & (K Units)
    Table 38. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2023-2028) & (K Units)
    Table 39. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Sales Channel (2017-2022)
    Table 40. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Sales Channel (2023-2028)
    Table 41. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2017-2022) & (US$ Million)
    Table 42. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2023-2028) & (US$ Million)
    Table 43. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Sales Channel (2017-2022)
    Table 44. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Sales Channel (2023-2028)
    Table 45. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Sales Channel (2017-2022) & (USD/Unit)
    Table 46. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price Forecast by Sales Channel (2023-2028) & (USD/Unit)
    Table 47. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2017-2022) & (K Units)
    Table 48. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2023-2028) & (K Units)
    Table 49. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2017-2022) & (US$ Million)
    Table 50. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2023-2028) & (US$ Million)
    Table 51. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2017-2022) & (K Units)
    Table 52. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2023-2028) & (K Units)
    Table 53. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2017-2022) & (US$ Million)
    Table 54. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2023-2028) & (US$ Million)
    Table 55. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2017-2022) & (K Units)
    Table 56. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2023-2028) & (K Units)
    Table 57. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2017-2022) & (US$ Million)
    Table 58. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2023-2028) & (US$ Million)
    Table 59. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2017-2022) & (K Units)
    Table 60. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2023-2028) & (K Units)
    Table 61. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2017-2022) & (US$ Million)
    Table 62. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2023-2028) & (US$ Million)
    Table 63. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2017-2022) & (K Units)
    Table 64. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2023-2028) & (K Units)
    Table 65. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2017-2022) & (US$ Million)
    Table 66. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2023-2028) & (US$ Million)
    Table 67. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2017-2022) & (K Units)
    Table 68. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2023-2028) & (K Units)
    Table 69. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2017-2022) & (US$ Million)
    Table 70. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2023-2028) & (US$ Million)
    Table 71. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2017-2022) & (K Units)
    Table 72. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2023-2028) & (K Units)
    Table 73. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2017-2022) & (US$ Million)
    Table 74. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2023-2028) & (US$ Million)
    Table 75. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2017-2022) & (K Units)
    Table 76. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2023-2028) & (K Units)
    Table 77. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2017-2022) & (US$ Million)
    Table 78. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2023-2028) & (US$ Million)
    Table 79. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2017-2022) & (K Units)
    Table 80. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2023-2028) & (K Units)
    Table 81. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2017-2022) & (US$ Million)
    Table 82. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2023-2028) & (US$ Million)
    Table 83. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2017-2022) & (K Units)
    Table 84. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2023-2028) & (K Units)
    Table 85. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2017-2022) & (US$ Million)
    Table 86. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2023-2028) & (US$ Million)
    Table 87. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2017-2022) & (K Units)
    Table 88. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2023-2028) & (K Units)
    Table 89. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2017-2022) & (US$ Million)
    Table 90. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2023-2028) & (US$ Million)
    Table 91. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2017-2022) & (K Units)
    Table 92. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2023-2028) & (K Units)
    Table 93. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2017-2022) & (US$ Million)
    Table 94. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2023-2028) & (US$ Million)
    Table 95. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2017-2022) & (K Units)
    Table 96. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2023-2028) & (K Units)
    Table 97. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2017-2022) & (US$ Million)
    Table 98. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2023-2028) & (US$ Million)
    Table 99. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2017-2022) & (K Units)
    Table 100. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2023-2028) & (K Units)
    Table 101. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2017-2022) & (US$ Million)
    Table 102. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2023-2028) & (US$ Million)
    Table 103. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2017-2022) & (K Units)
    Table 104. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2023-2028) & (K Units)
    Table 105. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2017-2022) & (US$ Million)
    Table 106. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2023-2028) & (US$ Million)
    Table 107. Bausch Health Corporation Information
    Table 108. Bausch Health Description and Major Businesses
    Table 109. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 110. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 111. Bausch Health Recent Developments
    Table 112. Allergan Corporation Information
    Table 113. Allergan Description and Major Businesses
    Table 114. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 115. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 116. Allergan Recent Developments
    Table 117. Sebela Pharmaceuticals Corporation Information
    Table 118. Sebela Pharmaceuticals Description and Major Businesses
    Table 119. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 120. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 121. Sebela Pharmaceuticals Recent Developments
    Table 122. Astellas Pharmaceuticals Corporation Information
    Table 123. Astellas Pharmaceuticals Description and Major Businesses
    Table 124. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 125. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 126. Astellas Pharmaceuticals Recent Developments
    Table 127. Amneal Pharms Corporation Information
    Table 128. Amneal Pharms Description and Major Businesses
    Table 129. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 130. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 131. Amneal Pharms Recent Developments
    Table 132. Pharscin Pharma Corporation Information
    Table 133. Pharscin Pharma Description and Major Businesses
    Table 134. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 135. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
    Table 136. Pharscin Pharma Recent Developments
    Table 137. Key Raw Materials Lists
    Table 138. Raw Materials Key Suppliers Lists
    Table 139. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors List
    Table 140. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customers List
    Table 141. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Trends
    Table 142. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Drivers
    Table 143. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Challenges
    Table 144. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Restraints
    Table 145. Research Programs/Design for This Report
    Table 146. Key Data Information from Secondary Sources
    Table 147. Key Data Information from Primary Sources
List of Figures
    Figure 1. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Picture
    Figure 3. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Type in 2021 & 2028
    Figure 3. XIFAXAN Product Picture
    Figure 4. Viberzi Product Picture
    Figure 5. Lotronex Product Picture
    Figure 6. Other Product Picture
    Figure 7. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Sales Channel in 2021 & 2028
    Figure 8. Hospitals Pharmacy
    Figure 9. Retail Pharmacy
    Figure 10. Other
    Figure 11. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Report Years Considered
    Figure 12. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales 2017-2028 (K Units)
    Figure 13. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 14. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue 2017-2028 (US$ Million)
    Figure 15. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region in Percentage: 2021 Versus 2028
    Figure 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2017-2022)
    Figure 17. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2023-2028)
    Figure 18. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales YoY (2017-2028) & (K Units)
    Figure 19. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue YoY (2017-2028) & (US$ Million)
    Figure 20. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales YoY (2017-2028) & (K Units)
    Figure 21. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue YoY (2017-2028) & (US$ Million)
    Figure 22. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales YoY (2017-2028) & (K Units)
    Figure 23. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue YoY (2017-2028) & (US$ Million)
    Figure 24. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales YoY (2017-2028) & (K Units)
    Figure 25. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue YoY (2017-2028) & (US$ Million)
    Figure 26. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales YoY (2017-2028) & (K Units)
    Figure 27. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue YoY (2017-2028) & (US$ Million)
    Figure 28. The Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
    Figure 29. The Top 5 and 10 Largest Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in the World: Market Share by Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue in 2021
    Figure 30. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
    Figure 31. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2017-2028)
    Figure 32. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2017-2028)
    Figure 33. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2017-2028)
    Figure 34. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Sales Channel (2017-2028)
    Figure 35. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2017-2028)
    Figure 36. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2017-2028)
    Figure 37. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2017-2028)
    Figure 38. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Sales Channel (2017-2028)
    Figure 39. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Country (2017-2028)
    Figure 40. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Country (2017-2028)
    Figure 41. U.S. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2017-2028) & (US$ Million)
    Figure 42. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2017-2028) & (US$ Million)
    Figure 43. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2017-2028)
    Figure 44. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2017-2028)
    Figure 45. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2017-2028)
    Figure 46. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Sales Channel (2017-2028)
    Figure 47. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Country (2017-2028)
    Figure 48. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Country (2017-2028)
    Figure 49. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2017-2028) & (US$ Million)
    Figure 50. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2017-2028) & (US$ Million)
    Figure 51. U.K. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2017-2028) & (US$ Million)
    Figure 52. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2017-2028) & (US$ Million)
    Figure 53. Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2017-2028) & (US$ Million)
    Figure 54. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2017-2028)
    Figure 55. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2017-2028)
    Figure 56. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2017-2028)
    Figure 57. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Sales Channel (2017-2028)
    Figure 58. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Region (2017-2028)
    Figure 59. Asia Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Region (2017-2028)
    Figure 60. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2017-2028) & (US$ Million)
    Figure 61. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2017-2028) & (US$ Million)
    Figure 62. South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2017-2028) & (US$ Million)
    Figure 63. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2017-2028) & (US$ Million)
    Figure 64. Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2017-2028) & (US$ Million)
    Figure 65. Taiwan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2017-2028) & (US$ Million)
    Figure 66. Indonesia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2017-2028) & (US$ Million)
    Figure 67. Thailand Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2017-2028) & (US$ Million)
    Figure 68. Malaysia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2017-2028) & (US$ Million)
    Figure 69. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2017-2028)
    Figure 70. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2017-2028)
    Figure 71. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2017-2028)
    Figure 72. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Sales Channel (2017-2028)
    Figure 73. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Country (2017-2028)
    Figure 74. Latin America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Country (2017-2028)
    Figure 75. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2017-2028) & (US$ Million)
    Figure 76. Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2017-2028) & (US$ Million)
    Figure 77. Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2017-2028) & (US$ Million)
    Figure 78. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2017-2028)
    Figure 79. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2017-2028)
    Figure 80. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2017-2028)
    Figure 81. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Sales Channel (2017-2028)
    Figure 82. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Country (2017-2028)
    Figure 83. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Country (2017-2028)
    Figure 84. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2017-2028) & (US$ Million)
    Figure 85. Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2017-2028) & (US$ Million)
    Figure 86. UAE Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2017-2028) & (US$ Million)
    Figure 87. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Chain
    Figure 88. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Process
    Figure 89. Channels of Distribution
    Figure 90. Distributors Profiles
    Figure 91. Bottom-up and Top-down Approaches for This Report
    Figure 92. Data Triangulation
    Figure 93. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Bausch Health
Allergan
Sebela Pharmaceuticals
Astellas Pharmaceuticals
Amneal Pharms
Pharscin Pharma
Frequently Asked Questions
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Sorting Machines

Sorting Machines market is segmented by Type and by Application. Players, stakeholders, and other ... Read More

Floor

Floor market is segmented by Type and by Application. Players, stakeholders, and other participan ... Read More